Navigating advanced therapy development for rare diseases is challenging from many perspectives and requires a customised development strategy. Advanced therapies - referred to as advanced therapy medicinal products (ATMPs) in the EU and as cell and gene therapies (CGT) in the US – are medicinal products based on genes, tissues or cells. Advanced therapies are especially promising for the long-term treatment or even durable solution of the underlying - often genetic - cause of rare diseases. However, compounding challenges of manufacturing and clinical development necessitate a regulatory strategy that diverges from traditional pathways. This blog provides a regulatory roadmap that identifies relevant meetings, applications and resources that can help an advanced therapy for rare disease achieve approval in the US and EU.
Sponsors should engage throughout clinical trial development with the relevant regulatory bodies to navigate the unique challenges and opportunities that come with the development of advanced therapies for rare disease. During the preclinical and clinical stages of development, meetings with regulatory agencies can guide trial design and accelerate development. For example, the US and EU offer expert scientific consultation on protocol design for rare disease advanced therapies during preclinical development. This scientific advisory protocol assistance can be conducted simultaneously, with advisors from the European Medicines Agency and FDA both present. The list of relevant meetings sponsors can have with regulatory bodies in the US and EU to ensure streamlined clinical development are as follows:
Manufacturing
- Innovative Task Force Meeting (EU) – advice on regulatory, technical and scientific issues specific to innovative medicine development
- CATT (US) – addresses regulatory challenges associated with development of advanced technologies for manufacturing and testing products
- INTERACT (US) – preliminary consultation on early stage development of investigational products
Pre-clinical
- Scientific advisory protocol assistance (US, EU) – consultation on protocol design and considerations for clinical development
- Pre-IND (US) – feedback informs the preparation of the investigational new drug (IND) application to authorise clinical development
- SPA (US) – feedback helps determine whether a clinical trial could lead to market authorisation
Pre-approval
- EOP I and/or EOP 2 (US) – feedback on whether an ongoing trial is sufficient for marketing authorisation or accelerated approval
- Pre-BLA (US) – consultation on technical issues with submission of biologics licence application (BLA) to streamline upcoming review
In addition to regulatory meetings, there are a number of certifications, designations and classifications that are likely to be relevant for rare disease advanced therapies. These applications can help to ensure your clinical development is appropriately resourced, that your therapeutic is appropriately expedited and that the challenges associated with rare disease and advanced therapies are accounted for during review of clinical trial authorisation and market authorisation submissions. The list of applications often relevant for rare disease advanced therapies are as follows:
Pre-clinical
- Orphan drug designation (EU, US) - provides government assistance for development of drugs that treat exceedingly uncommon conditions, which may otherwise not be a commercially viable propoisition
- ATMP classification (EU) - helps developers to clarify the development path and the applicable regulatory framework based on the advanced therapies proposed mechanism of action
- PRIME designation (EU) - provides accelerated pathway for clinical development, where appropriate
- Fast track designation (US) - provides accelerated pathway for clinical development, where appropriate
Pre-approval
- RMAT designation (US) - provides accelerated pathway for regenerative medicines
- ATMP certification (EU) - determines whether additional studies are needed for marketing authorisation approval and streamlines review process
- Priority Review (US) - accelerated review of market authorisation application (MAA)
- Rolling Review (US) - allows for staggered submission of market authorisation application
Sponsors of rare disease advanced therapies may also need to include additional information in their clinical trial (IND in the US; CTA in the EU) and marketing approval applications (BLA in the US; MAA in the EU). For gene therapies developed in the EU, an environmental risk assessment and genetically modified organism summary are needed for clinical trial application approval. In addition, paediatric drug development plans are a legal requirement for all new drugs in the US and EU, depending on the ages of the intended participants, although the US can make exemptions for orphan designated products.
In this fast-moving area, support from experts in clinical trial development of rare disease advanced therapies will ensure that your therapeutic development and regulatory strategy are sound.
For more information on unlocking the potential of advanced therapies developed for rare diseases, read our whitepaper and review our blog about clinical development challenges.
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel